Bob Mauch

So the cryogenic...

therapy, the real-time monitoring of what's going on with that, that's still required.

And it's a capability that we have in a pretty unique way, given the scale that we have, you know, both primarily within North America and Western Europe.

So we can do that at a scale that others can't.

And that's another example of, you know, one of the questions you asked earlier, Drew, is just how we're continually investing.

So we want to make sure that we're out

and from with the latest technology.

So it's a different business model.

It's a different technology, but I think the logistics of it is still critical.

It's an important question for us strategically and tactically.

First of all, we're

We're a purpose-driven organization and enterprise, and our purpose is that we're united in our responsibility to create healthier futures.

So that means to us that we have to continually find ways to enhance the process by which patients get access to pharmaceuticals.

But your point about beyond distribution, that also means to us that we are not just distribution, that we are an end-to-end healthcare services provider.

And so you can look on both ends.

We've actually talked about the work that we're doing to continue to enhance our capabilities in distribution, but that's also happening in conversations with pharma companies.

So that's a strategic relationship that we develop with pharmaceutical companies broadly or a specific brand.

within that company.

And there are lots of services within that.

So I mentioned clinical trial support.